Table 3.

Herpes zoster incidence, burden of disease, and vaccine availability in countries with developing economies.

Country	ZVL license year	RZV license year	Year HZ vaccine in schedule	Eligible age	Vaccine(s) currently in use	Estimated annual incidence per 1000 person years (age range)	Estimated annual cost of HZ a (Direct b /Indirect c ), in millions
Asia
China	–	2019	–	50+ 110	RZV	2015–17: 6.64 [50+, Mainland China] 2000–08: 2.9–5.8 [50+, Taiwan] 5.7–6.2 [all ages, Taiwan] 110	–/ $219.16 (mainland China) 111
Malaysia	2012	–	2014	60–79, 50–59 optional 112	ZVL	–	–
Philippines	2012	–	2012	60+ 113	ZVL	–	–
Thailand	2012	–	2014	60+	ZVL	2007–8: 0.3 [All ages] 114	Per case: $120.21 114 /–
Europe
Poland	2006	2018			ZVL	3.39 [all ages], 6.14 [50+] 115
Latin America and The Caribbean
Argentina	2012	–	?	50+ 116	ZVL	2000–5: 3.57 (all ages)117,118	Per case: $856.34/$1011.14 119
Brazil	2012	–	–	?	ZVL	2000–5: 5.62 (all ages) 118	Per case: $1264.03/$575.90 119
Mexico	2012	–	–	?	ZVL		Per case: $788.36/$437.83 119
Middle East and Central Asia
Qatar	?	–			ZVL	2012–17: 0.362 (all ages) 120

HZ, herpes zoster; RZV, recombinant zoster vaccine, or Shingrix; VZV, varicella-zoster virus; ZVL, zoster vaccine live, or Zostavax.

^aCost of HZ and its complications (e.g. PHN).

^bDirect costs include cost to healthcare system and/or direct medical costs.

^cIndirect costs include societal costs incurred due to loss of productivity (e.g. time away from work).